# JX02002 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/jx02002

> JX02002, sponsored by Milestone Pharmaceuticals Inc. (MIST): 1 recorded catalyst.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | JX02002 |
| Codes | JX02002 |
| Sponsor | Milestone Pharmaceuticals Inc. (MIST) https://sec-api.dev/companies/mist/catalysts |
| Indications | psvt in china |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### September 6, 2024: topline data readout

- Status: completed, positive. Date confidence: exact. Stage: 3. Indication: PSVT in China.
- First seen 2024-11-12, last confirmed 2025-11-12.
- SEC Form 10-Q (accession 0001558370-24-015147): "On September 6, 2024, our licensing partner, Corxel (formerly Ji Xing Pharmaceuticals Limited, JIXING), a clinical-stage biopharmaceutical company announced positive topline data from the Phase 3 JX02002 clinical trial of etripamil nasal spray in patients with PSVT in China." https://www.sec.gov/Archives/edgar/data/1408443/000155837024015147/mist-20240930x10q.htm
- SEC Form 10-Q (accession 0001104659-25-109689): "In September 2024, our licensing partner, Corxel (formerly Ji Xing Pharmaceuticals Limited, JIXING), a clinical-stage biopharmaceutical company, announced positive topline data from the Phase 3 (JX02002) clinical trial of etripamil nasal spray in patients with PSVT in China." https://www.sec.gov/Archives/edgar/data/1408443/000110465925109689/mist-20250930x10q.htm
- SEC Form 10-Q (accession 0001558370-25-011141): "In September 2024, our licensing partner, Corxel (formerly Ji Xing Pharmaceuticals Limited, JIXING), a clinical-stage biopharmaceutical company, announced positive topline data from the Phase 3 (JX02002) clinical trial of etripamil nasal spray in patients with PSVT in China." https://www.sec.gov/Archives/edgar/data/1408443/000155837025011141/mist-20250630x10q.htm
- SEC Form 10-Q (accession 0001558370-25-007648): "In September 2024, our licensing partner, Corxel (formerly Ji Xing Pharmaceuticals Limited, JIXING), a clinical-stage biopharmaceutical company announced positive topline data from the Phase 3 JX02002 clinical trial of etripamil nasal spray in patients with PSVT in China." https://www.sec.gov/Archives/edgar/data/1408443/000155837025007648/mist-20250331x10q.htm
- SEC Form 10-K (accession 0001558370-25-002849): "In September 2024, our licensing partner, Corxel (formerly Ji Xing Pharmaceuticals Limited, JIXING), a clinical-stage biopharmaceutical company announced positive topline data from the Phase 3 JX02002 clinical trial of etripamil nasal spray in patients with PSVT in China." https://www.sec.gov/Archives/edgar/data/1408443/000155837025002849/mist-20241231x10k.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/jx02002.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "JX02002 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/jx02002

```bibtex
@misc{secapidev_pdufa_jx02002_20261116,
  title        = {JX02002 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/jx02002}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_jx02002_20261116","title":"JX02002 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/jx02002","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
